Johnson & Johnson
JNJ.N- Latest Trade
- trading lower175.5USD
- Change
- -3.32
- % Change
1.86%Negative
- Day Range
- 175.17 - 179.35
- 52-Week Range
- 155.72 - 186.69
As of May 19 2022. Values delayed up to 15 minutes
- Previous Close
- 178.82
- Open
- 178.84
- Volume
- 2,322,883.00
- 3 Month Average Trading Volume
- 164.58
- Shares Out (Mil)
- 2,631.40
- Market Cap
- 470,547.30
- Forward P/E
- 17.44
- Dividend Yield
- 2.53
Key Statistics
2.26315789 mean rating - 19 analysts
- P/E Excl. Extra Items (TTM)
- 24.09
- Price To Sales (TTM)
- 4.96
- Price To Book (Quarterly)
- 6.29
- Price To Cash Flow (Per Share TTM)
- 17.37
- Total Debt/Total Equity (Quarterly)
- 44.37
- Long Term Debt/Equity (Quarterly)
- 38.62
- Return On Investment (TTM)
- 14.88
- Return On Equity (TTM)
- 11.30
2021 (millions USD)
About Johnson & Johnson
Company Information
Johnson & Johnson is a holding company that is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. The Company operates through three segments: Consumer Health, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being. The Consumer Health segment includes a range of products that is focused on personal healthcare used in the skin health/beauty, over-the-counter medicines, baby care, oral care, women’s health and wound care markets. The Pharmaceutical segment is focused on six therapeutic areas: Immunology, Infectious Diseases, Neuroscience, Oncology, Cardiovascular and Metabolism and Pulmonary Hypertension. The Medical Devices segment includes a range of products used in the interventional solutions, orthopaedics, surgery, and vision fields. Its geographic area includes the United States, Europe, Western Hemisphere (excluding the United States), and Africa, Asia and Pacific.
Address
One Johnson & Johnson PlazaNEW BRUNSWICK, NJ
08933
United States
Industry
Biotechnology & Drugs
Executive Leadership
- Alex Gorsky
- Executive Chairman of the Board
- Joaquin Boix Duato
- Chief Executive Officer, Director
- Joseph J. Wolk
- Chief Financial Officer, Executive Vice President
- Peter M. Fasolo
- Chief Human Resource Officer, Executive Vice President
- James Swanson
- Executive Vice President, Chief Information Officer
- Michael H. Ullmann
- Executive Vice President, General Counsel
- Vanessa Broadhurst
- Executive Vice President, Global Corporate Affairs
- William N. Hait
- Executive Vice President, Chief External Innovation, Medical Safety, Global Public Health Officer
- Mathai Mammen
- Executive Vice President, Pharmaceuticals, R&D
- Ashley Mcevoy
- Executive Vice President - Worldwide Chairman, Medical Devices
- Thibaut Mongon
- Executive Vice President, Worldwide Chairman, Consumer Health
- Jennifer L. Taubert
- Executive Vice President - Worldwide Chairman, Pharmaceuticals
- Kathryn E. Wengel
- Executive Vice President, Chief Global Supply Chain Officer
- Anne M. Mulcahy
- Lead Independent Director
- Darius Adamczyk
- Independent Director
- Mary Catherine Beckerle
- Independent Director
- D. Scott Davis
- Independent Director
- Ian E. L. Davis
- Independent Director
- Jennifer A. Doudna
- Independent Director
- Marillyn A. Hewson
- Independent Director
- Hubert Joly
- Independent Director
- Mark B. Mcclellan
- Independent Director
- A. Eugene Washington
- Independent Director
- Mark A. Weinberger
- Independent Director
- Nadja Y. West
- Independent Director
Latest News
Markets Performance
Official Data PartnerCommodities
| Future | Last | % Change |
|---|---|---|
| Gold | 1,815.90 | -- |
| Copper | 755.80 | 1.28%Negative |
| Brent Crude Oil | 109.11 | -- |
| CBOT Soybeans | 1,662.75 | -- |
Stocks
| Index | Last | % Change |
|---|---|---|
| S&P 500 | 3,923.68 | 4.04%Negative |
| Euro STOXX 50 | 3,690.74 | 1.36%Negative |
| FTSE 100 | 7,438.09 | 1.07%Negative |
| Nikkei 225 | 26,911.20 | -- |
Source: Refinitiv, an LSEG business - data delayed by at least 15 minutes